Interventional Glaucoma

A Korean study identified preoperative use of preservative-containing glaucoma medications as a significant risk factor for trabeculectomy failure in POAG patients. The Glaucoma Medication Intensity Index (GMII) predicted long-term outcomes, highlighting the importance of managing medication exposure before surgery.

A higher body mass index was protective against glaucoma progression, while patients who were underweight had significantly faster rates of structural loss

While studies of obesity and tobacco and alcohol consumption showed that many chronic diseases are affected by the factors being studied, none had mentioned an effect on glaucoma progression.

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-oriented, multispecialty ophthalmology CME conference, along with a newly introduced optometry track. Henderson sits down with Ophthalmology Times to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular hypertension. Designed for implantation during cataract surgery, the platform delivers bimatoprost to lower intraocular pressure for up to 3 years.

This retrospective cohort study was designed to provide further information on the association between BP parameters and VF progression over time.

Program director and co-founder Bonnie An Henderson, MD, sits down with Ophthalmology Times to talk about how the annual conference is a unique blend of cutting-edge science, professional growth, and community. The 2025 conference will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

The weekly drug-eluting contact lens was created by the company’s proprietary 3D printing technology and met all primary endpoints with no serious adverse events reported in either cohort.

Omar Salamanca, MD, staff ophthalmologist, Orbis Flying Eye Hospital, discusses Orbis's tailored glaucoma training programs, which focus on hands-on surgical skills, early detection, telemedicine, and personalized follow-up care, helping underserved regions improve glaucoma management and blindness prevention.

Robert T. Chang, MD, from Stanford University discusses how large language models are transforming ophthalmology by enhancing patient communication, documentation, and education, while also addressing ethical considerations and potential future applications in glaucoma care.

Two glaucoma specialists discuss pairing patients with the right procedures

Moving on from medication “stacks” and the old-school reactive approach

Vikas Chopra, MD, focused on minimally invasive glaucoma surgery (MIGS) and its significance in enhancing glaucoma treatment. He highlighted how MIGS allows ophthalmologists to perform interventions at an earlier stage and with increased safety, resulting in improved patient outcomes.

Victoria L. Tseng, MD, PhD, discusses SLT, microshunts and what glaucoma specialists can learn from large data sets

The study, conducted in 2022, highlights significant variations in glaucoma prevalence across different demographic groups, states, and counties.

In visual field progression results, SLT was superior to ocular drops as first-line treatment for patients with glaucoma

At this year's American Academy of Ophthalmology (AAO) meeting, John Berdahl, MD, spoke about the recent clinical trials of travoprost and its use in patients with prior SLT.

While anxiety and depression may cause vision loss, physicians can offer hope

Moon Jeong Lee, MD, shares how volunteering in geriatric care shaped her career path.

The option gives Glaukos exclusive global license agreements on pre-agreed terms, including upfront and milestone payments plus royalties.

Ripple will lead preclinical development of RTC-620 while AbbVie will lead the clinical and commercialization activities upon exercise of option-to-license agreement.

According to the company, topline results will be presented at the 2024 American Academy of Ophthalmology Annual Meeting, being held October 18 to 21 in Chicago, Illinois.

German researchers found that their study results suggest that the effect of glaucoma on the elapsed time depends on disease progression. This uncertainty during everyday navigation tasks may adversely affect patients’ quality of life.

Common glaucoma treatments may worsen ocular surface disease and meibomian gland dysfunction, leading to discomfort, redness, and even poor treatment compliance.

Push to identify biomarkers for earlier diagnosis, new therapeutic targets.